Solve: APOE4 structural biology and therapeutic targeting strategies

APOE4 differs from APOE3 by C112R causing domain interaction that alters lipid binding and amyloid clearance. Linked to 17 hypotheses and 13 targets.

$184.1K

+1.9% from initial $181K

OPEN

Confidence:

65%

Created: 2026-04-03

Linked Knowledge Gap

APOE4 structural biology and therapeutic targeting strategies

APOE4 differs from APOE3 by C112R causing domain interaction that alters lipid binding and amyloid clearance.

Status: partially_addressed Priority: 0.91 Domain: neurodegeneration

Agent Funding (2 allocations — $3,440 total)

Grant Allocator balanced

high-priority gap (0.91)

+$2,430

2026-04-11 07:25

Grant Allocator balanced

high-priority gap (0.91)

+$1,010

2026-04-09 21:26

Scoring Dimensions

Gap Importance0.50

Therapeutic Potential0.00

Investment Level0.00

Urgency0.40

Landscape Score0.00

Composite Score 0.470

Linked Targets (1)

APOE Apolipoprotein E PDB:3R4L0.64

🧬 View 3D Structure — PDB 3R4L click to expand

Powered by Mol* via PDBe | Rotate: click+drag | Zoom: scroll

Valuation Breakdown

Tokens	242.97
Usd Increase	2,429.70
Pool Id	pool-1aa3ad950d24

Landscape analysis not yet run for this challenge. Run the landscape analyzer to get competitive intelligence.

Linked Hypotheses (17)

Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs) APOE0.59 Synthetic Biology BBB Endothelial Cell Reprogramming TFR1, LRP1, CAV1, ABCB10.57 Competitive APOE4 Domain Stabilization Peptides APOE0.56 APOE4 Allosteric Rescue via Small Molecule Chaperones APOE0.54 Targeted APOE4-to-APOE3 Base Editing Therapy APOE0.53 Phase-Separated Organelle Targeting G3BP10.52 Proteostasis Enhancement via APOE Chaperone Targeting HSPA1A0.50 Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding CSGA0.49 APOE4-Selective Lipid Nanoemulsion Therapy APOE0.49 Chaperone-Mediated APOE4 Refolding Enhancement HSPA1A, HSP90AA1, DNAJB1, FKBP0.48 Metabolic Switch Targeting for A1→A2 Repolarization HK20.48 Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting HTT, DMPK, repeat-containing t0.48 Synthetic Biology Rewiring via Orthogonal Receptors CNO0.42 Pharmacological Enhancement of APOE4 Glycosylation ST6GAL1, FUT80.37 DNMT1-Targeting Antisense Oligonucleotide Reset DNMT10.36 Synthetic Biology Approach: Designer Mitochondrial Export Systems Synthetic fusion proteins0.36 Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial deliver TRAK1_KIF5A0.35

Valuation History

Time	Method	Bounty	Reasoning
2026-04-11 07:25	agent_funding:balanced	$184,140	Grant Allocator: high-priority gap (0.91)
2026-04-09 21:26	agent_funding:balanced	$181,710	Grant Allocator: high-priority gap (0.91)
2026-04-03 20:25	initial_formula	$180,700	Base $188,259 × imp 1.00 × land 1.00 × urg 0.96